Instead of approving the new Alzheimer’s drug donanemab this month, as was expected, the U.S. Food and Drug Administration will now require the experimental medication be scrutinized more closely...
Monoclonal antibodies provide small benefits in Alzheimer’s disease
Jan 26, 2024
Harms include increased risks for amyloid-related imaging abnormalities (ARIA)-edema, ARIA-hemorrhage and symptomatic ARIA-edema.
High BP visit-to-visit variability linked to dementia risk in late life
Oct 31, 2023
Higher blood pressure variability was not associated with higher lifetime dementia risk at age 60, 70 or 80 years.
Finger prick, venous blood can ID key Alzheimer’s disease biomarkers
Jul 20, 2023
Capillary and venous dry blood spot can identify glial fibrillary acidic protein, neurofilament light and phosphorylated tau.
FDA gives full approval to Alzheimer’s disease drug Leqembi
Jul 06, 2023
Although Leqembi did help reduce mental decline compared with placebo, the drug has been linked to two deaths from brain bleeds.
Genetic links seen for HDL cholesterol, systolic BP with Alzheimer’s disease
May 17, 2023
Genetically determined high-density lipoprotein cholesterol and systolic blood pressure were linked to increased odds of Alzheimer’s disease.
FDA approves first drug meant to ease Alzheimer’s disease-llnked agitation
May 11, 2023
Patients who received 2 or 3 mg of Rexulti had significant improvements in agitation scores compared with patients taking a placebo.
FDA approves second drug for Alzheimer’s disease, despite safety concerns
Jan 06, 2023
The approval of lecanemab-irmb (Leqembi) comes after controversial approval in 2021 of aducanumab (Aduhelm), which met with criticism over concerns about that drug’s effectiveness, safety and pricing.
New drug for Alzheimer’s disease shows promise in phase 3 trial
Sep 28, 2022
Lecanemab is a monoclonal antibody drug designed to target and help remove Alzheimer’s-associated amyloid plaques in the brain.
Effect of noradrenergic drugs explored in Alzheimer’s disease
Jul 29, 2022
Meta-analyses suggest positive effects of noradrenergic drugs on global cognition and apathy.